RATIONAL DRUG DESIGN OF POTENT V600E-BRAF KINASE INHIBITORS THROUGH MOLECULAR DOCKING SIMULATION

B-RAF is a one of the RAF protein kinase group that contribute to the development of different types of cancer. V600E-BRAF protein has lot potential for scientific investigation as the therapeutic target owing to its participation in melanoma cancer and is the molecular target of many anticancer co...

Full description

Saved in:
Bibliographic Details
Main Authors: Bello Abdullahi Umar, Adamu Uzairu, Gideion Adamu Shallangwa, Sani Uba
Format: Article
Language:English
Published: Universidade Federal de Viçosa (UFV) 2019-12-01
Series:The Journal of Engineering and Exact Sciences
Subjects:
Online Access:https://periodicos.ufv.br/jcec/article/view/8460
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832569694214684672
author Bello Abdullahi Umar
Adamu Uzairu
Gideion Adamu Shallangwa
Sani Uba
author_facet Bello Abdullahi Umar
Adamu Uzairu
Gideion Adamu Shallangwa
Sani Uba
author_sort Bello Abdullahi Umar
collection DOAJ
description B-RAF is a one of the RAF protein kinase group that contribute to the development of different types of cancer. V600E-BRAF protein has lot potential for scientific investigation as the therapeutic target owing to its participation in melanoma cancer and is the molecular target of many anticancer compounds like quinolinylaminopyrimidines (QAP) derivatives. In this research, interactions of QAP derivatives with V600E-BRAF kinase were modeled and predicted using molecular docking simulation approach with the help of Autodock vina version 4.0 of Pyrx software. The molecular docking simulation result of this research shows that QAP6 (?11.7 kcalmol-1) best inhibit V600E-BRAF when compared with other QAP analogous within the dataset and was found to be better than the standard V600E-BRAF inhibitor vemurafenib (-11.3 kcalmol-1). This compound (QAP6) were further used in designing novel and potent V600E-BRAF inhibitors by attaching substituents to the quinoline ring of the compound. Moreover, the two newly designed inhibitors N1 and N2 with a binding energy of ?12.7 kcalmol-1 and –12.9 kcalmol-1 respectively were found to be more potent than the parent structure QAP6 (?11.7 kcalmol-1) and the standard V600E-BRAF inhibitor vemurafenib (-11.3 kcalmol-1). Thus; this study provides a valuable approach and new direction to novel drug discovery. There is hope in the future studies to include the synthesis and evaluation of these newly designed inhibitors which can establish them to be the most potent V600E-BRAF inhibitors and efficient ant-melanoma cancer drug.
format Article
id doaj-art-d64b9f83b5594fcb98f9198f79334a9f
institution Kabale University
issn 2527-1075
language English
publishDate 2019-12-01
publisher Universidade Federal de Viçosa (UFV)
record_format Article
series The Journal of Engineering and Exact Sciences
spelling doaj-art-d64b9f83b5594fcb98f9198f79334a9f2025-02-02T19:58:38ZengUniversidade Federal de Viçosa (UFV)The Journal of Engineering and Exact Sciences2527-10752019-12-015510.18540/jcecvl5iss5pp0469-0481RATIONAL DRUG DESIGN OF POTENT V600E-BRAF KINASE INHIBITORS THROUGH MOLECULAR DOCKING SIMULATIONBello Abdullahi UmarAdamu UzairuGideion Adamu ShallangwaSani Uba B-RAF is a one of the RAF protein kinase group that contribute to the development of different types of cancer. V600E-BRAF protein has lot potential for scientific investigation as the therapeutic target owing to its participation in melanoma cancer and is the molecular target of many anticancer compounds like quinolinylaminopyrimidines (QAP) derivatives. In this research, interactions of QAP derivatives with V600E-BRAF kinase were modeled and predicted using molecular docking simulation approach with the help of Autodock vina version 4.0 of Pyrx software. The molecular docking simulation result of this research shows that QAP6 (?11.7 kcalmol-1) best inhibit V600E-BRAF when compared with other QAP analogous within the dataset and was found to be better than the standard V600E-BRAF inhibitor vemurafenib (-11.3 kcalmol-1). This compound (QAP6) were further used in designing novel and potent V600E-BRAF inhibitors by attaching substituents to the quinoline ring of the compound. Moreover, the two newly designed inhibitors N1 and N2 with a binding energy of ?12.7 kcalmol-1 and –12.9 kcalmol-1 respectively were found to be more potent than the parent structure QAP6 (?11.7 kcalmol-1) and the standard V600E-BRAF inhibitor vemurafenib (-11.3 kcalmol-1). Thus; this study provides a valuable approach and new direction to novel drug discovery. There is hope in the future studies to include the synthesis and evaluation of these newly designed inhibitors which can establish them to be the most potent V600E-BRAF inhibitors and efficient ant-melanoma cancer drug. https://periodicos.ufv.br/jcec/article/view/8460MelanomaQuinolinylaminopyrimidinesbinding energyPi–Pi interactionV600E-BRAF
spellingShingle Bello Abdullahi Umar
Adamu Uzairu
Gideion Adamu Shallangwa
Sani Uba
RATIONAL DRUG DESIGN OF POTENT V600E-BRAF KINASE INHIBITORS THROUGH MOLECULAR DOCKING SIMULATION
The Journal of Engineering and Exact Sciences
Melanoma
Quinolinylaminopyrimidines
binding energy
Pi–Pi interaction
V600E-BRAF
title RATIONAL DRUG DESIGN OF POTENT V600E-BRAF KINASE INHIBITORS THROUGH MOLECULAR DOCKING SIMULATION
title_full RATIONAL DRUG DESIGN OF POTENT V600E-BRAF KINASE INHIBITORS THROUGH MOLECULAR DOCKING SIMULATION
title_fullStr RATIONAL DRUG DESIGN OF POTENT V600E-BRAF KINASE INHIBITORS THROUGH MOLECULAR DOCKING SIMULATION
title_full_unstemmed RATIONAL DRUG DESIGN OF POTENT V600E-BRAF KINASE INHIBITORS THROUGH MOLECULAR DOCKING SIMULATION
title_short RATIONAL DRUG DESIGN OF POTENT V600E-BRAF KINASE INHIBITORS THROUGH MOLECULAR DOCKING SIMULATION
title_sort rational drug design of potent v600e braf kinase inhibitors through molecular docking simulation
topic Melanoma
Quinolinylaminopyrimidines
binding energy
Pi–Pi interaction
V600E-BRAF
url https://periodicos.ufv.br/jcec/article/view/8460
work_keys_str_mv AT belloabdullahiumar rationaldrugdesignofpotentv600ebrafkinaseinhibitorsthroughmoleculardockingsimulation
AT adamuuzairu rationaldrugdesignofpotentv600ebrafkinaseinhibitorsthroughmoleculardockingsimulation
AT gideionadamushallangwa rationaldrugdesignofpotentv600ebrafkinaseinhibitorsthroughmoleculardockingsimulation
AT saniuba rationaldrugdesignofpotentv600ebrafkinaseinhibitorsthroughmoleculardockingsimulation